(Q37292769)

19 August 2017

title

Deceptive imprinting and immune refocusing in vaccine design (English)

1 reference

19 August 2017

1 reference

1 reference

9

Marvin J Grubman

1 reference

19 August 2017

Gregory J Tobin

1

1 reference

19 August 2017

Jessie D Trujillo

2

1 reference

19 August 2017

Ruth V Bushnell

3

1 reference

19 August 2017

George Lin

4

1 reference

19 August 2017

A Ray Chaudhuri

5

1 reference

19 August 2017

Jinxue Long

6

1 reference

19 August 2017

Jose Barrera

7

1 reference

19 August 2017

Lindomar Pena

8

1 reference

19 August 2017

Peter L Nara

10

1 reference

19 August 2017

language of work or name

English

0 references

publication date

11 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

26

1 reference

19 August 2017

issue

49

1 reference

19 August 2017

page(s)

6189-6199

1 reference

Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Deceptive imprinting: a cosmopolitan strategy for complicating vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Deceptive imprinting: insights into mechanisms of immune evasion and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

7 January 2021

Toward an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

HIV-1: the confounding variables of virus neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Glycosylation of immunodominant linear epitopes in the carboxy-terminal region of the caprine arthritis-encephalitis virus surface envelope enhances vaccine-induced type-specific and cross-reactive neutralizing antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Antibody response to the surface envelope of caprine arthritis-encephalitis lentivirus: disease status is predicted by SU antibody isotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Neutralization-Resistant Antigenic Variants of Caprine Arthritis-Encephalitis Lentivirus Associated with Progressive Arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Accumulation of amino acid substitutions promotes irreversible structural changes in the hemagglutinin of human influenza AH3 virus during evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Interventions for the interruption or reduction of the spread of respiratory viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Generation and evaluation of reassortant influenza vaccines made by reverse genetics for H9N2 avian influenza in Korea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Crystal structures of influenza virus hemagglutinin in complex with high-affinity receptor analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Structure of influenza haemagglutinin at neutral and at fusogenic pH by electron cryo-microscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Homology model of the structure of influenza B virus HA1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Antigenic characterisation of H3N2 subtypes of the influenza virus by mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Influenza virus hemagglutinin--structural studies and their implications for the development of therapeutic approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

The presence of rhinovirus in lower airways of patients with bronchial asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

New developments in the epidemiology and clinical spectrum of rhinovirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Rhinovirus: more than just a common cold virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Crystallographic structural organization of human rhinovirus serotype 16, 14, 3, 2 and 1A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Structure of a neutralizing antibody bound bivalently to human rhinovirus 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Structure of a human rhinovirus-bivalently bound antibody complex: implications for viral neutralization and antibody flexibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Neutralization epitopes of human rhinovirus type 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Transmission pathways of foot-and-mouth disease virus in the United Kingdom in 2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Structural comparison of two strains of foot-and-mouth disease virus subtype O1 and a laboratory antigenic variant, G67.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

Preferential immune response to virion surface glycoproteins by caprine arthritis-encephalitis virus-infected goats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

inferred from DOI database lookup

7 January 2021

based on heuristic

Severity of arthritis is predicted by antibody response to gp135 in chronic infection with caprine arthritis-encephalitis virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

inferred from DOI database lookup

7 January 2021

based on heuristic

Antigenic variation of neutralization-sensitive epitopes of caprine arthritis-encephalitis lentivirus during persistent arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.080

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.09.080

1 reference

19 August 2017

1 reference